Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Consensus PT from Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is $30.50.

TYRA has been the subject of several research reports. Wedbush reiterated an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, January 13th. Finally, UBS Group initiated coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of Tyra Biosciences stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the transaction, the director now directly owns 447,857 shares in the company, valued at approximately $7,295,590.53. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 16,597 shares of company stock worth $270,500 over the last ninety days. Insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TYRA. Janus Henderson Group PLC acquired a new stake in shares of Tyra Biosciences during the 3rd quarter worth approximately $24,994,000. Walleye Capital LLC increased its stake in Tyra Biosciences by 306.5% during the 3rd quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock worth $2,976,000 after buying an additional 95,451 shares during the period. Polar Asset Management Partners Inc. bought a new stake in shares of Tyra Biosciences in the 3rd quarter worth about $2,071,000. FMR LLC boosted its stake in Tyra Biosciences by 0.8% during the 3rd quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after purchasing an additional 26,187 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Tyra Biosciences in the 3rd quarter worth approximately $593,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Down 4.2 %

Shares of Tyra Biosciences stock opened at $13.85 on Friday. The firm has a market capitalization of $700.81 million, a PE ratio of -8.60 and a beta of 1.05. The business’s 50-day moving average price is $15.26 and its 200-day moving average price is $18.93. Tyra Biosciences has a 12 month low of $13.27 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.